EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
×
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
QQQ   280.57 (-0.76%)
AAPL   141.17 (-2.11%)
MSFT   240.33 (-0.59%)
META   109.46 (+0.63%)
GOOGL   95.19 (-0.90%)
AMZN   92.42 (-1.63%)
TSLA   180.83 (-1.14%)
NVDA   156.39 (-1.19%)
NIO   10.50 (+3.75%)
BABA   79.86 (+5.25%)
AMD   73.39 (+0.27%)
T   19.01 (+1.01%)
MU   55.12 (-1.13%)
CGC   3.42 (+0.59%)
F   13.75 (+0.15%)
GE   85.66 (+0.22%)
DIS   94.69 (-1.05%)
AMC   7.43 (+1.36%)
PYPL   77.64 (-2.87%)
PFE   49.49 (-0.16%)
NFLX   280.96 (-0.07%)
NASDAQ:ATXI

Avenue Therapeutics - ATXI Stock Forecast, Price & News

$1.31
-0.06 (-4.38%)
(As of 11/29/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.30
$1.44
50-Day Range
$1.31
$67.50
52-Week Range
$1.30
$26.85
Volume
214,226 shs
Average Volume
1.34 million shs
Market Capitalization
$6.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Avenue Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
1.89% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
1.44mentions of Avenue Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

ATXI stock logo

About Avenue Therapeutics (NASDAQ:ATXI) Stock

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.

Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Stock News Headlines

Avenue Therapeutics Shareas Surge 160%
Avenue Therapeutics Spikes 168%
Avenue Therapeutics up 4% on 1-for-15 reverse stock split
See More Headlines
Receive ATXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATXI Company Calendar

Last Earnings
11/10/2022
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/24/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ATXI
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-3,730,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.72 per share

Miscellaneous

Free Float
4,741,000
Market Cap
$6.26 million
Optionable
Not Optionable
Beta
-0.57

Key Executives

  • Dr. Lindsay Allan Rosenwald (Age 67)
    Exec. Chairman
  • Dr. Xiaoqin Lu M.D. (Age 47)
    Consultant
    Comp: $699.33k
  • Dr. Alexandra MacLean M.D. (Age 55)
    Chief Exec. Officer
  • Mr. David Jin
    Interim CFO & COO
  • Dr. Scott A. Reines M.D. (Age 75)
    Ph.D., Interim Chief Medical Officer
  • Srinivas Subramanian
    Exec. VP













ATXI Stock - Frequently Asked Questions

How have ATXI shares performed in 2022?

Avenue Therapeutics' stock was trading at $13.62 at the beginning of 2022. Since then, ATXI stock has decreased by 90.4% and is now trading at $1.31.
View the best growth stocks for 2022 here
.

Are investors shorting Avenue Therapeutics?

Avenue Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 82,900 shares, a decline of 61.0% from the October 31st total of 212,600 shares. Based on an average trading volume of 4,330,000 shares, the short-interest ratio is currently 0.0 days. Approximately 1.9% of the shares of the stock are short sold.
View Avenue Therapeutics' Short Interest
.

When is Avenue Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 24th 2023.
View our ATXI earnings forecast
.

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its quarterly earnings data on Thursday, November, 10th. The company reported ($0.45) EPS for the quarter.

When did Avenue Therapeutics' stock split?

Avenue Therapeutics's stock reverse split on Friday, September 23rd 2022. The 1-15 reverse split was announced on Friday, September 23rd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 23rd 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Avenue Therapeutics own?
When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an IPO on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

Who are Avenue Therapeutics' major shareholders?

Avenue Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (2.42%) and Two Sigma Investments LP (0.97%). Insiders that own company stock include Invagen Pharmaceuticals, Inc, Joseph Walter Vazzano and Neil Herskowitz.
View institutional ownership trends
.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $1.31.

How much money does Avenue Therapeutics make?

Avenue Therapeutics (NASDAQ:ATXI) has a market capitalization of $6.26 million. The company earns $-3,730,000.00 in net income (profit) each year or ($3.7484) on an earnings per share basis.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 1140 Avenue of the Americas Floor 9, NEW YORK NY, 10036. The official website for the company is www.avenuetx.com. The company can be reached via phone at (781) 652-4500 or via email at ir@avenuetx.com.

This page (NASDAQ:ATXI) was last updated on 11/29/2022 by MarketBeat.com Staff